PRONEXUS (7893) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
21 Jul, 2026Executive summary
Revenue for the first three months ended June 30, 2025, increased 1.2% year-over-year to ¥11,938 million, driven by higher demand for English translation services and increased printed materials for shareholder meetings.
Operating profit declined 2.0% year-over-year to ¥3,167 million due to higher labor and personnel costs.
Profit before tax dropped 31.4% year-over-year to ¥3,209 million, reflecting the absence of a prior-year gain on sale of investments.
Profit attributable to owners of parent decreased 31.8% year-over-year to ¥2,178 million.
Financial highlights
Gross profit rose 0.7% year-over-year to ¥5,468 million, as revenue growth outpaced cost increases.
Cost of sales increased 1.6% year-over-year to ¥6,469 million, mainly from higher labor costs.
Selling, general and administrative expenses rose 4.5% year-over-year to ¥2,311 million, primarily due to increased personnel expenses.
Basic earnings per share for the quarter was ¥85.37, down from ¥125.13 a year earlier.
Outlook and guidance
Full-year revenue forecast for FY2026 is ¥31,800 million, up 2.6% year-over-year.
Full-year profit attributable to owners of parent is projected at ¥1,800 million, a 299.1% increase year-over-year, reflecting a low prior-year base.
No changes have been made to previously announced earnings forecasts.
A special dividend of ¥2.00 per share is planned for the second quarter to commemorate the 95th anniversary.
Latest events from PRONEXUS
- Revenue up 5.3% YoY to ¥12,567 million, but profit attributable to owners fell 1.9%.7893
Q1 202731 Jul 2026 - Profit before tax surged 46.9% year-over-year, driven by a major gain on sale of investments.7893
Q1 202521 Jul 2026 - First-half profit surged 57% year-over-year, boosted by investment gains and strong IR demand.7893
Q2 202521 Jul 2026 - Profit surged on higher IR service demand and investment gains, with guidance reaffirmed.7893
Q3 202521 Jul 2026 - Profit dropped sharply on impairment loss, but revenue and segment growth remain solid.7893
Q4 202521 Jul 2026 - Revenue up 3%, profit down 34% year-over-year; treasury share buyback and special dividends planned.7893
Q2 202621 Jul 2026 - Revenue up, profit down year-over-year; outlook cautious amid market and customer base shifts.7893
Q3 202621 Jul 2026 - Revenue and profit rebounded sharply, with strong outlook despite rising costs.7893
Q4 202621 Jul 2026